Down-regulation of miR-223 reverses epithelial-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. - Wikidata - awgldk - TriplyDB

Down-regulation of miR-223 reverses epithelial-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells.

Down-regulation of miR-223 reverses epithelial-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells.

http://www.wikidata.org/entity/Q35176428

about

Targeting Epithelial-Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer New Insights into the Crossroads between EMT and Stemness in the Context of Cancer Noncoding RNAs and pancreatic cancer ΔNp63α and microRNAs: leveraging the epithelial-mesenchymal transition Molecular Drivers of Pancreatic Cancer Pathogenesis: Looking Inward to Move Forward.Curcumin suppresses cell growth and invasion and induces apoptosis by down-regulation of Skp2 pathway in glioma cells Deep sequencing identifies deregulation of microRNAs involved with vincristine drug-resistance of colon cancer cells MiR-625-3p promotes cell migration and invasion via inhibition of SCAI in colorectal carcinoma cells.Noninvasive urinary miRNA biomarkers for early detection of pancreatic adenocarcinoma Toward targeted therapy in chemotherapy-resistant pancreatic cancer with a smart triptolide nanomedicine.Synergistic reversal effect of epithelial-to-mesenchymal transition by miR-223 inhibitor and genistein in gemcitabine-resistant pancreatic cancer cells.miR-101 targeting ZFX suppresses tumor proliferation and metastasis by regulating the MAPK/Erk and Smad pathways in gallbladder carcinoma Rottlerin exhibits anti-cancer effect through inactivation of S phase kinase-associated protein 2 in pancreatic cancer cells.Role of Notch signaling pathway in pancreatic cancer.MiRNA-145 increases therapeutic sensibility to gemcitabine treatment of pancreatic adenocarcinoma cells.Rottlerin exhibits antitumor activity via down-regulation of TAZ in non-small cell lung cancer.Suppression of CIP4/Par6 attenuates TGF-β1-induced epithelial-mesenchymal transition in NRK-52E cells.S-phase kinase-associated protein 2 promotes cell growth and motility in osteosarcoma cells.BRCA1 expression serves a role in vincristine resistance in colon cancer cells.MicroRNAs and Cancer Drug Resistance.MicroRNA in pancreatic cancer.Approaches for targeting cancer stem cells drug resistance.Epigenetics of epithelial-to-mesenchymal transition in pancreatic carcinoma.Epithelial-mesenchymal transition as a therapeutic target for overcoming chemoresistance in pancreatic cancer.Recent progress on the effects of microRNAs and natural products on tumor epithelial-mesenchymal transition.miR-206 regulates cisplatin resistance and EMT in human lung adenocarcinoma cells partly by targeting MET Inhibition of Notch-1 pathway is involved in rottlerin-induced tumor suppressive function in nasopharyngeal carcinoma cells.Crosstalk between the Notch signaling pathway and non-coding RNAs in gastrointestinal cancers.miR-133b reverses cisplatin resistance by targeting GSTP1 in cisplatin-resistant lung cancer cells.Cell division cycle 20 promotes cell proliferation and invasion and inhibits apoptosis in osteosarcoma cells.Arsenic trioxide inhibits cell growth and motility via up-regulation of let-7a in breast cancer cells.MiR-26b reverses temozolomide resistance via targeting Wee1 in glioma cells.MiR-30a-5p confers cisplatin resistance by regulating IGF1R expression in melanoma cells.miR-1266 Contributes to Pancreatic Cancer Progression and Chemoresistance by the STAT3 and NF-κB Signaling Pathways.Clinical significance of miRNA - 106a in non-small cell lung cancer patients who received cisplatin combined with gemcitabine chemotherapy.Non-Coding RNAs and Resistance to Anticancer Drugs in Gastrointestinal Tumors.

P2860

Q26741846-9F2E3D5D-864F-49F2-9E32-2967FCEC9D2F Q26764831-E2713E1D-8922-49ED-8D6F-D89F29DB172A Q26774630-0E09F062-470D-4986-AC61-981B55BD7A68 Q28077508-ED951D9A-8C5A-449C-A4C8-B79D3452EB87 Q33624574-589AC679-0124-479C-B111-1A6C9FA2A14B Q36228504-7F9D9DC1-84AA-46FB-8B02-EA779C4526C0 Q36261916-85E16A1A-3105-4334-9348-866D83E1EBB8 Q36413914-CDCBCF49-90D7-4B08-84FF-9AF79CC28503 Q36420185-90F95A87-582F-4FCA-9176-0D55C3C4B836 Q36946804-77EF22BC-CA25-48CA-A396-F96980429200 Q37077423-866BB26D-077A-43F3-9217-D55BAA2E03E6 Q37225543-BD2D2BF6-7730-46B1-9C4D-1CEAA301CC0B Q37382511-09AE7D5B-F4C8-452E-87C0-78CEA3337964 Q37679979-5CBB1705-C43D-4E5C-B5F0-4C1CABC59569 Q37688623-024E3079-A96D-46DE-B740-38011FA46D9C Q37702621-EEF0C79B-0718-423C-A43A-CADD8A1ADEB6 Q38604585-9B8279C2-3A1F-4E6F-9B0D-A3A84F089CB4 Q38644806-357D4210-6F37-46E0-8373-C29F03CDF049 Q38697693-93CC8690-A2FC-419F-8B33-9B62B21B21C4 Q38748118-8172662A-AA5E-4485-B19C-2331F23285C3 Q38850617-FE4CAB8D-5528-4658-B6CC-1DFC93516D02 Q38971795-E9A0B4FD-2E2D-4C2F-9806-8FE6C16B3F6B Q39108676-EF8C37AA-F22D-4E19-AD0E-AAEE6AE372FD Q39112764-A4A1665B-D010-4D20-80B8-7C9E91021E1B Q39458257-47B93722-BAB1-46E5-8E48-3408AAA84AC1 Q41134348-CD2512D7-3136-4009-8FE9-61CCFE70E8B3 Q42365327-2442BBE9-4957-4E01-B200-8449CA64F1C6 Q47101032-B0F5379F-4407-4BA1-8DBA-A1CB84187395 Q48540173-86C42C0E-2B66-4468-944E-BD311536E757 Q49584310-BB3BEC77-731C-4E70-8C57-84247CAD2FB4 Q49584338-9D7712D4-BAE3-4E47-A9A8-CD3D703D0562 Q50133239-4170DB9B-CD36-4539-9FC6-F3B078E1E5E5 Q52720005-54F764CA-F6E7-4D28-B6D4-1CB1029C56A6 Q55368106-E6F1164D-B36D-4B9F-A9AA-705A53117028 Q55399368-16FA5A91-FF7C-4CA3-B5BD-7521B0CED8EE Q55403266-BB6E7776-7ABE-4F66-9BB5-AFB06A95E4AF

P2860

Down-regulation of miR-223 reverses epithelial-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells.

http://www.wikidata.org/entity/Q35176428

description

2015 nî lūn-bûn

@nan

2015 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Down-regulation of miR-223 rev ...... stant pancreatic cancer cells.

@ast

Down-regulation of miR-223 rev ...... stant pancreatic cancer cells.

@en

type

label

Down-regulation of miR-223 rev ...... stant pancreatic cancer cells.

@ast

Down-regulation of miR-223 rev ...... stant pancreatic cancer cells.

@en

prefLabel

Down-regulation of miR-223 rev ...... stant pancreatic cancer cells.

@ast

Down-regulation of miR-223 rev ...... stant pancreatic cancer cells.

@en

P1433

Q35176428-50BAB916-609D-49E1-9849-0E4BA0CC85BF

P1476

Q35176428-984A542D-83F3-4D16-8155-08A3BF194F74

P2093

Q35176428-088DB1D7-DD32-4A92-9D21-F09E7CF33B26

Q35176428-281CEBC8-8DED-49F3-9805-D1A25AF5FC8F

Q35176428-3972C3FB-B85E-41FD-951C-AA4A150D3678

Q35176428-5CDB1DC9-F390-4F46-A6F7-6B745A3FFC93

Q35176428-6D944CC3-5B40-474D-9159-B8EF8DC1BA8F

Q35176428-72CE3CB2-E3D7-49BA-B29D-CB8E71F3655B

Q35176428-924595C8-740A-49F0-82D1-4A9108F23DA4

Q35176428-9F6C6F65-3C0A-4799-9BA7-5D62BC80F204

Q35176428-A6B9EAC3-9B6C-4488-8865-30771D53A889

Q35176428-CEE10D47-B6DA-473D-A5A6-9EAC51556653

P2860

Q35176428-006BC3A0-64F1-4E92-AF87-4DFA840434A2

Q35176428-0456BCC9-2D76-433D-829E-7889CD447CE7

Q35176428-0CDBD171-EE61-4746-8FC5-4BC802FD1FB3

Q35176428-0FD5224B-E994-4940-9E21-A2696EC82903

Q35176428-11A0DD4D-1860-4051-BE29-93F76510DD46

Q35176428-19A443D3-56D0-4C5B-924D-7BABD9DAEDD9

Q35176428-1D9B204B-0401-49EE-87A6-DAB5DCBDA5C5

Q35176428-257DD416-CFAF-473D-8DC3-670E9A78502C

Q35176428-3BEC0D08-2ECA-4230-8B89-C8904344AAD5

Q35176428-3D899D4F-4471-4638-985C-E1421F402BD3

P304

Q35176428-ED8DC235-C17A-4FBF-A327-1C73E5E0222F

P31

Q35176428-526548DF-01B0-4EBC-8135-8D27E4806589

P356

Q35176428-998AC9AD-B0FF-46EE-AEC1-C2230C5C16F3

P407

Q35176428-A359B144-51E7-4202-9786-BCBF5DE41D5E

P433

Q35176428-6ACA3D08-12C7-418B-B1A0-D61226009AE4

P478

Q35176428-47B02A1F-216A-4BE0-BF6D-0CD8C6A8C05D

P577

Q35176428-3FD6B678-4D63-49B3-BC10-0E1B79A265AF

P5875

Q35176428-3485281F-8051-422F-85E9-938C78E641A4

P698

Q35176428-0AD8D802-8E25-400C-A762-F01FA3E53D4D

P932

Q35176428-38BF4299-9BDD-4C51-B2C2-638C8A30F999

P356

ONCOTARGET.2714

P1433

P1476

Down-regulation of miR-223 rev ...... stant pancreatic cancer cells.

@en

P2093

Bin Yin

http://www.w3.org/2001/XMLSchema#string

Binbin Fang

http://www.w3.org/2001/XMLSchema#string

Cong Ma

http://www.w3.org/2001/XMLSchema#string

Fanpeng Zeng

http://www.w3.org/2001/XMLSchema#string

Haijie Pang

http://www.w3.org/2001/XMLSchema#string

Hui Wang

http://www.w3.org/2001/XMLSchema#string

Jia Ma

http://www.w3.org/2001/XMLSchema#string

Jun Xia

http://www.w3.org/2001/XMLSchema#string

Long Cheng

http://www.w3.org/2001/XMLSchema#string

Ying Shi

http://www.w3.org/2001/XMLSchema#string

P2860

Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells

Molecular mechanisms of epithelial-mesenchymal transition

Epithelial-mesenchymal transitions in development and disease

Cancer statistics, 2014

Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer

Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistance.

TWIST and ovarian cancer stem cells: implications for chemoresistance and metastasis

MiR-489 regulates chemoresistance in breast cancer via epithelial mesenchymal transition pathway.

miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy.

Notch-1 induces epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells

P304

1740-1749

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.2714

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2015-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

271707790

http://www.w3.org/2001/XMLSchema#string

P698

25638153

http://www.w3.org/2001/XMLSchema#string

P932

4359328

http://www.w3.org/2001/XMLSchema#string